Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gp120 protein
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral, Intranasal
01
Overview
gp120 protein, in the context of NIAID-sponsored clinical research, refers to the HIV-1 envelope glycoprotein expressed by the Ad4-EnvC150 vaccine vector. Ad4-EnvC150 is a recombinant, replication-competent adenovirus serotype 4 (Ad4) vector encoding the gp120 subunit derived from a clade C HIV-1 isolate. This vaccine candidate is designed to elicit both mucosal and systemic immune responses against HIV-1 by mimicking natural infection through the adenovirus vector's replication. It is typically administered orally (via capsules) or intranasally to target mucosal surfaces, which are primary sites of HIV entry. The development is led by the National Institute of Allergy and Infectious Diseases (NIAID) for the prevention of HIV infection.
- Other names
- HIV-1 envelope glycoprotein gp120HIV1 envelope glycoprotein gp120HIV 1 envelope glycoprotein gp120Ad4-EnvC150 recombinant adenovirusAd-4-EnvC150 recombinant adenovirusAd 4-EnvC150 recombinant adenovirus
02
Targets
CCR5 (C-C chemokine receptor type 5)Env (HIV-1 envelope glycoprotein)HIV-1 envelope glycoprotein V3 glycan supersiteDC-SIGN (Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))CD4 (T lymphocyte surface antigen)CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on gp120 protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gp120 protein.